TrialCancer science2020

Alectinib for relapsed or refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: An open-label phase II trial.

Reiji Fukano et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.